Search

Author/Creator Merkus, Petrus

1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Issue 10212 (23rd November 2019)

Authors:
Heijerman, Harry G M; McKone, Edward F; Downey, Damian G; Van Braeckel, Eva; Rowe, Steven M; Tullis, Elizabeth; Mall, Marcus A; Welter, John J; Ramsey, Bonnie W; McKee, Charlotte M; Marigowda, Gautham; Moskowitz, Samuel M; Waltz, David; Sosnay, Patrick R; Simard, Christopher; Ahluwalia, Neil; Xua...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1940
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021)

Authors:
Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne...
Journal:
Lancet
Issue:
Volume 9:Issue 7(2021)
Page Start:
733
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search